Loading...
•
Dec 31, 2020
Jazz Pharmaceuticals Q4 2020 Earnings Report
Jazz Pharmaceuticals reported Q4 2020 earnings with total revenues increasing by 14% and launched Xywav in the U.S.
Key Takeaways
Jazz Pharmaceuticals announced its Q4 2020 financial results, with total revenues increasing by 14% compared to the same period in 2019. The company highlighted the successful U.S. launches of Zepzelca and Xywav and provided full year 2021 total revenue guidance of $2.55 Billion to $2.70 Billion.
Total revenues increased 14% in the fourth quarter of 2020 compared to the same period in 2019.
Neuroscience net product sales in the fourth quarter of 2020 increased 6% compared to the same period in 2019, driven by the launch of Xywav.
Oncology net product sales in the fourth quarter of 2020 increased 46% compared to the same period in 2019, led by Zepzelca net product sales.
The company expects 2021 to be another catalyst-rich year as they focus on their ambitious set of objectives.
Revenue by Segment
Forward Guidance
Jazz Pharmaceuticals provided full year 2021 financial guidance on a standalone basis and does not reflect the impact of the proposed acquisition of GW Pharmaceuticals. They plan to provide updated guidance following the close of the planned transaction.
Positive Outlook
- Revenues $2,550 - $2,700 million
- Total net product sales $2,540 - $2,685 million
- Neuroscience $1,785 - $1,885 million
- Oncology $715 - $835 million
- Net income per diluted share $8.30 - $10.45
Challenges Ahead
- SG&A expenses $1,032 - $1,100 million
- SG&A expenses as % of total revenues 38% - 43%
- R&D Expenses $365 - $410 million
- R&D expenses as % of total revenues 14% - 16%
- Effective tax rate 18% - 20%
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...